Last reviewed · How we verify
Fingolimod Reference Formulation
At a glance
| Generic name | Fingolimod Reference Formulation |
|---|---|
| Also known as | Gylenia® |
| Sponsor | Asofarma S.A.I. y C. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Oral Bio-equivalence Study (PHASE1)
- Bioequivalence Study of a Test Capsule Formulation of Fingolimod With the Reference Capsule Formulation of Fingolimod (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fingolimod Reference Formulation CI brief — competitive landscape report
- Fingolimod Reference Formulation updates RSS · CI watch RSS
- Asofarma S.A.I. y C. portfolio CI